Lexicon Pharmaceuticals Quarterly Balance Sheet
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Lexicon Pharmaceuticals financial position
As of Jun 30, 2026, Lexicon Pharmaceuticals reported total assets of $250.1 million, up 10.9% from a year earlier against total liabilities of $75.5 million. Shareholders' equity stood at $174.5 million, or 69.8% of assets. The company held $40.9 million in cash and equivalents against $51.4 million of debt, a net debt position of $10.5 million.
The current ratio (current assets divided by current liabilities) was 13.37, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.29.
Summary generated from market data by MetaCap's automated system. Methodology
Lexicon Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 40.92M | 38.09M | 34.33M | 49.66M | 21.36M | 62.89M | 66.66M | 34.55M | 35.62M | 96.49M | 22.46M | 21.12M |
| Short-Term Investments | 149.69M | 132.57M | 61.90M | 66.29M | 117.64M | 131.95M | 171.30M | 223.82M | 274.35M | 259.10M | 147.56M | 197.31M |
| Receivables | 1.64M | 11.78M | 2.38M | 2.33M | 2.18M | 47.45M | 3.47M | 2.90M | 2.62M | 1.53M | 1.01M | 318.00K |
| Inventory | 1.20M | 276.00K | 281.00K | 158.00K | 168.00K | 201.00K | 231.00K | 636.00K | 585.00K | 514.00K | 381.00K | 336.00K |
| Total Current Assets | 196.58M | 186.03M | 101.89M | 122.53M | 145.08M | 245.81M | 246.19M | 268.61M | 320.84M | 364.65M | 176.55M | 223.37M |
| Property, Plant & Equipment | 1.65M | 1.75M | 1.86M | 1.98M | 2.13M | 2.31M | 2.48M | 2.13M | 1.95M | 1.84M | 1.99M | 2.13M |
| Goodwill | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Total Assets | 250.06M | 268.82M | 184.99M | 205.93M | 225.58M | 297.67M | 298.42M | 321.12M | 373.36M | 417.22M | 229.43M | 276.48M |
| Accounts Payable | 2.34M | 3.00M | 3.08M | 3.80M | 5.90M | 10.69M | 14.80M | 14.20M | 12.22M | 8.07M | 14.39M | 12.04M |
| Short-Term Debt | 0 | 0 | 4.59M | — | — | 42.06M | 0 | — | — | — | — | — |
| Total Current Liabilities | 14.71M | 9.90M | 20.87M | 21.72M | 34.84M | 110.69M | 45.25M | 36.05M | 27.88M | 23.40M | 31.55M | 32.26M |
| Long-Term Debt | 51.44M | 49.68M | 49.41M | 56.51M | 56.11M | 58.64M | 100.30M | 99.89M | 99.50M | 99.87M | 99.51M | 99.27M |
| Total Liabilities | 75.53M | 65.96M | 77.45M | 85.77M | 96.14M | 174.64M | 152.47M | 142.61M | 133.38M | 128.35M | 136.32M | 136.97M |
| Shareholders' Equity | 174.53M | 202.86M | 107.54M | 120.16M | 129.44M | 123.03M | 145.95M | 178.51M | 239.98M | 288.87M | 93.11M | 139.51M |
| Retained Earnings | -2.05B | -2.02B | -2.02B | -2.00B | -1.99B | -1.99B | -1.97B | -1.93B | -1.87B | -1.82B | -1.77B | -1.72B |
| Total Debt | 51.44M | 49.68M | 54.00M | 56.51M | 56.11M | 100.70M | 100.30M | 99.89M | 99.50M | 99.87M | 99.51M | 99.27M |
| Net Cash (Debt) | 139.17M | 120.97M | 42.23M | 59.44M | 82.90M | 94.14M | 137.66M | 158.47M | 210.47M | 255.72M | 70.52M | 119.16M |
| Shares Outstanding | 446.87M | 425.71M | 365.85M | 365.78M | — | — | 363.02M | — | — | — | — | — |
This table shows 12 quarterly periods of Lexicon Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow LXRX's reporting calendar. What is a balance sheet?